PPT-Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine

STEAL Switch NRTIs to Tenofovir DFEmtricitabine or AbacavirLamivudine STEAL Study Design Source Martin A et al Clin Infect Dis 2009491591 1601 Study Design STEAL Background. GENERIC ARVs. Tim Horn. Treatment Action Group. tim.horn@treatmentactiongroup.org. Federal AIDS Policy Partnership Meeting. December 2014. Patents and Exclusivity 101 . Myriad Policies. Patents issued >1996 have term of 20 years. Brian R. Wood, MD. Assistant Professor of Medicine, University of Washington. Medical Director, NW AETC ECHO. Last Updated. : April 16, 2015. Source: . HHS . Antiretroviral Therapy Guidelines. . AIDS Info (www.aidsinfo.nih.gov). Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 3rd Quarter. October-December 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus . 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study. Michael Aboud,. 1. Richard Kaplan,. of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 1. st. Quarter. APRIL-JUNE 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. ACTIVITY CODE . TD342. Antiretroviral Medications: . What . you need to know. Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP. Associate Professor, Department of Pharmacy Practice. 2 NRTIs in Treatment-Experienced. M97-765 Trial. Lopinavir. -RTV + . Nevirapine. + 2 NRTIs in Treatment-Experienced . M97-765: . Study Design. Source. : . Benson CA, et al. . J . Infect. . Dis. . 2002;185:599-607.. Professor Francois Venter. Ezintsha, University of the Witwatersrand, Johannesburg, South Africa. Thanks to: The Ezintsha team, HE²RO, Sydney Rosen, Anna . Grismrud. , Phumla . Sinxabi. , Andrew Hill, Gary Maartens, Mohammed Ali, Mark Siedner, Elvin Geng, Aaloke Mody, Jeff Wing, Vince Marconi, Yogan Pillay, Liesel Page-Shipp, Thato Chidarikire. Virologically. Suppressed. OLE Trial. LPV-RTV + . 3TC vs. LPV. -RTV + 2 NRTIs. in . Virologically. Suppressed. OLE: . Study Design. Source: . Arribas. JR, et al. . Lancet Infect Dis. . 2015;15:. 785-92.. by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg. E Duke. https://www.hiv.uw.edu/page/treatment/drugs. David . Spach’s. National HIV Curriculum. HIV . Virion. ssRNA. Reverse Transcriptase. Integrase. HIV . Virion. CD4 T Lymphocyte. Human CD4+ T cell. ADONE Trial. Simplification to Efavirenz-Tenofovir DF-Emtricitabine . ADONE: Study Design. Source: . Airoldi. M, et al. Patient Prefer Adherence. 2010;4:115-25.. Study Design: ADONE Study . Background. DRIVE FORWARD. Doravirine. + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs. DRIVE FORWARD: Design. Source: Molina J-M, et al. Lancet HIV. 2018;5:e211-20.. Doravirine. + 2 NRTIs. (n = 385). Darunavir + RTV + 2 NRTIs.